Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in IgM MGUS Anti-MAG Polyneuropathy
2023-505933-29-00Phase 2Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in monoclonal gammopathy of undetermined significance (MGUS) and anti-myelin-associated glycoprotein neuropathy, sponsored by University Medical Center Utrecht. Primary endpoints: Neurological response by INCAT disability score at 12 months, Incidence of adverse events and 2 more. Planned start Oct 2023; status: authorised.
02
Drugs
zanubrutinib
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)anti-myelin-associated glycoprotein neuropathy
Beyond the preview
Go deeper on 2023-505933-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505933-29-00.